IL133176A0 - Pharmaceutical compositions of peptides having low solubility in physiological medium - Google Patents

Pharmaceutical compositions of peptides having low solubility in physiological medium

Info

Publication number
IL133176A0
IL133176A0 IL13317698A IL13317698A IL133176A0 IL 133176 A0 IL133176 A0 IL 133176A0 IL 13317698 A IL13317698 A IL 13317698A IL 13317698 A IL13317698 A IL 13317698A IL 133176 A0 IL133176 A0 IL 133176A0
Authority
IL
Israel
Prior art keywords
peptides
pharmaceutical compositions
low solubility
physiological medium
physiological
Prior art date
Application number
IL13317698A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/en
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL133176A0 publication Critical patent/IL133176A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL13317698A 1997-05-28 1998-05-26 Pharmaceutical compositions of peptides having low solubility in physiological medium IL133176A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (en) 1997-05-28 1997-05-28 Pharmaceutical compositions of peptides having low solubility in physiological medium
EP97121246A EP0880969A1 (en) 1997-05-28 1997-12-03 Pharmaceutical compositions of peptides having low solubility in physiological medium
PCT/EP1998/003079 WO1998053844A1 (en) 1997-05-28 1998-05-26 Pharmaceutical compostions of peptides having low solubility in physiological medium

Publications (1)

Publication Number Publication Date
IL133176A0 true IL133176A0 (en) 2001-03-19

Family

ID=26145485

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13317698A IL133176A0 (en) 1997-05-28 1998-05-26 Pharmaceutical compositions of peptides having low solubility in physiological medium
IL133176A IL133176A (en) 1997-05-28 1999-11-28 Pharmaceutical preparations containing peptides in a low solubility vessel in a physiological medium

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL133176A IL133176A (en) 1997-05-28 1999-11-28 Pharmaceutical preparations containing peptides in a low solubility vessel in a physiological medium

Country Status (26)

Country Link
US (1) US6331520B1 (cs)
EP (2) EP0880969A1 (cs)
JP (1) JP2002502384A (cs)
KR (1) KR100552546B1 (cs)
CN (1) CN1159062C (cs)
AR (1) AR012868A1 (cs)
AT (1) ATE252909T1 (cs)
AU (1) AU743152B2 (cs)
BG (1) BG64668B1 (cs)
BR (1) BR9809708A (cs)
CA (1) CA2291765A1 (cs)
CZ (1) CZ298825B6 (cs)
DE (1) DE69819322T2 (cs)
DK (1) DK0984788T3 (cs)
EA (1) EA002227B1 (cs)
EE (1) EE04001B1 (cs)
ES (1) ES2210772T3 (cs)
IL (2) IL133176A0 (cs)
NO (1) NO323697B1 (cs)
NZ (1) NZ500777A (cs)
PL (1) PL192647B1 (cs)
PT (1) PT984788E (cs)
SI (1) SI0984788T1 (cs)
SK (1) SK284640B6 (cs)
TR (1) TR199902865T2 (cs)
WO (1) WO1998053844A1 (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
US20080249017A1 (en) * 2007-04-04 2008-10-09 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
CN104918927B (zh) * 2012-10-12 2018-09-07 莱雅公司 含有至少一种水溶助长剂和至少一种活性化合物的化妆品组合物
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
BR112018016774A2 (pt) 2016-02-16 2018-12-26 Strongbridge Ireland Limited veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio
KR20210062638A (ko) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신의 안정한 비강내 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
DE69019534T2 (de) * 1989-12-21 1995-09-21 Novonordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
ATE197126T1 (de) * 1991-08-26 2000-11-15 Abbott Lab Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacologically active compounds in delayed release agents.
TW280770B (cs) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
WO1996010417A1 (en) * 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
NO995763L (no) 1999-11-24
KR100552546B1 (ko) 2006-02-14
SK159799A3 (en) 2000-07-11
DE69819322D1 (de) 2003-12-04
CN1159062C (zh) 2004-07-28
CN1263469A (zh) 2000-08-16
CZ298825B6 (cs) 2008-02-20
PL336982A1 (en) 2000-07-31
AU743152B2 (en) 2002-01-17
CZ423199A3 (cs) 2000-05-17
JP2002502384A (ja) 2002-01-22
SI0984788T1 (en) 2004-02-29
BG103884A (en) 2000-07-31
EA199901089A1 (ru) 2000-06-26
IL133176A (en) 2006-08-01
EE04001B1 (et) 2003-04-15
DE69819322T2 (de) 2004-07-29
ATE252909T1 (de) 2003-11-15
NZ500777A (en) 2001-09-28
EP0984788A1 (en) 2000-03-15
NO323697B1 (no) 2007-06-25
EE9900545A (et) 2000-06-15
EA002227B1 (ru) 2002-02-28
EP0984788B1 (en) 2003-10-29
HK1029928A1 (en) 2001-04-20
WO1998053844A1 (en) 1998-12-03
DK0984788T3 (da) 2004-03-08
KR20010012253A (ko) 2001-02-15
ES2210772T3 (es) 2004-07-01
AR012868A1 (es) 2000-11-22
BR9809708A (pt) 2000-07-11
TR199902865T2 (xx) 2000-05-22
SK284640B6 (sk) 2005-08-04
NO995763D0 (no) 1999-11-24
US6331520B1 (en) 2001-12-18
AU8106298A (en) 1998-12-30
EP0880969A1 (en) 1998-12-02
CA2291765A1 (en) 1998-12-03
PT984788E (pt) 2004-01-30
BG64668B1 (bg) 2005-11-30
PL192647B1 (pl) 2006-11-30

Similar Documents

Publication Publication Date Title
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
HUS1200028I1 (hu) 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek
IL135177A0 (en) Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
HUP9701018A3 (en) Xantine derivatives having (omega-amino)-hydroxyalkynyl side-chain and pharmaceutical compositions containing them
IL136044A0 (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
HUP0001269A3 (en) 2-oxo-1-azetidine sulfonic acid derivatives and combined pharmaceutical compositions thereof
IL114925A0 (en) Glycinamide derivatives their preparation and pharmaceutical compositions containing them
HUP0002510A3 (en) Tetrazole derivatives and pharmaceutical compositions containing them
IL133176A0 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
HU9701437D0 (en) Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive anzymes
HU9800147D0 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
IL124661A0 (en) 5'-Deoxy-cytidine derivatives their preparation and pharmaceutical compositions containing them
HUP0100085A3 (en) Biphenylamidine derivatives and pharmaceutical compositions containing them
AP2001002371A0 (en) Streptogramin derivatives preparation and compositions containing them
ZA9811655B (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
IL125908A0 (en) Peptides and pharmaceutical compositions comprising same
HUP0004223A3 (en) 4-oxo-butynic acids and pharmaceutical composition containing them as active agent
IL131266A0 (en) Peptides and pharmaceutical compositions comprising same
ZA982952B (en) Pseudo-peptide compounds their preparation and use in pharmaceutical formulations
HUP0002118A3 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees